Which Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings?

2 min read | May 23, 2025 06:18 PM AEST | By Team Kalkine Media

Google News:

Which Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings? — Image source: Shutterstock

Recent News

Zip Shares Push Higher as Market Watches Key Turning Point

Could These Under-the-Radar ASX Stocks Be Worth Watching?

ASX 200 Soars as Trump Signals Surprise Iran Peace Shift

Which ASX Small Caps Are Making Early Moves Today?

Make Kalkine Media
My Trusted Source

Highlights

Healthcare sector exposure under S&P/ASX 200 and ASX All Ordinaries led by CSL (CSL)

Over ten percent of global funds include this issuer despite high market valuations

Global footprint and recurring revenue streams drive widespread portfolio inclusion

Operating in the healthcare sector under the S&P/ASX 200 and ASX All Ordinaries, CSL (ASX:CSL) stands out as the sole issuer held by more than ten percent of global fund managers, even as Australian equities rank among the world’s most expensive markets.

Sector Positioning

CSL operates within the healthcare domain, supplying plasma-derived therapies and vaccine products to a network of international markets. Inclusion under both major equity benchmarks reflects its substantial market capitalisation and diversified revenue base, anchored by long-term supply agreements and research collaborations.

Global Fund Adoption

Despite elevated valuation multiples across the Australian market, this issuer maintains a pervasive presence in global fund portfolios. Institutional investors cite steady cashflow generation and resilience of underlying demand for biotherapeutic products as key attributes justifying allocation, even where broader market entry costs remain high.

Operational Footprint

A vertically integrated model underpins production capacity, with manufacturing sites in North America, Europe and Asia. This geographic diversification supports uninterrupted supply chains for critical therapies, reinforcing investor confidence in the stability of revenue streams and enabling CSL’s widespread listing in fund mandates.

Financial Resilience

Revenue contributions from immunoglobulin therapies and specialty vaccines deliver recurring income under multi-year contracts with healthcare systems and private insurers. Research-and-development partnerships further bolster the pipeline of next-generation treatments, underpinning the issuer’s capacity to sustain dividend distributions and fund capital investments.

Index Impact

Quotation of this healthcare staple under the S&P/ASX Two Hundred and ASX All Ordinaries carries significant weight in sector-based subindices. Its prevalence in global funds amplifies its influence on market sentiment, while inclusion benchmarks offer a barometer for institutional positioning within the domestic equity landscape.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.